Participated · Series B · Nov 2025

Founded in 2018, Washington-DC–based Sorcero offers an Agentic AI platform—comprising Sorcero Medical, SciComms, Safety and Medtech—that is specifically trained on life-science data and built to meet stringent regulatory and privacy requirements. The system unifies hundreds of global data sources to create a 360° view of more than 40 million healthcare professionals and 100 million scientists, enabling customers to analyze 263 million publications and 1.3 billion citations for real-time insights. One-third of the top 30 global pharmaceutical firms use Sorcero, achieving up to 92 % productivity gains in evidence generation, 72 % faster insight discovery, and publication timelines shortened by two to five months. The platform delivers 96.1 % clinical inclusion accuracy—exceeding FDA regulatory thresholds and PhD-level human performance. Sorcero’s offerings support medical affairs, safety, scientific communications, and medical devices, and are available directly and through channels such as the Google Cloud Marketplace and NIH STRIDES. Recent strategic moves include the acquisition of Axiom Health to bolster its med-device capabilities and partnerships with Google Cloud, Springer Nature, ServiceNow, USDM Life Sciences, and Snowflake. With a cumulative $59 million raised, the company plans to scale globally and further develop its insight-driven engagement model for precision medicine.

Participated · Equity · Jan 2023

Gastrograph AI offers a predictive human sensory perception platform powered by the company’s proprietary sensory database and machine‑learning algorithms. The company launched SensoryLink, a web‑based interactive Platform as a Service (PaaS), to let users visualize and act on predictive insights. Its system delivers full‑cycle capabilities from curated data collection via a mobile app to high‑resolution predictions of flavor, aroma, and texture preferences across demographic segments. The platform is aimed at helping food and beverage companies create new products, optimize brands, and enter new markets with targeted flavor profiles. Gastrograph AI positions its insights as actionable, real‑time consumer preference information to speed decision‑making for major CPG firms. The company is described in filings as Analytical Flavor Systems, Inc., and is New York–based. Gastrograph AI provides predictive analytics for food and beverage companies, using machine learning to forecast how consumers will perceive flavors. The company collects data from professional tasters across 600–1,000 variables per tasting covering aroma, flavor and texture to build high-resolution taste profiles. It uses those profiles to recommend product reformulations for different demographics and to guide new product development in target markets. More than 75% of Gastrograph’s customers are outside the U.S., with 50% in Asia, and the company is based in New York City. Gastrograph has a partnership with Cornes Technology that began after Cornes approached the startup in 2015 and the two spent two years developing the relationship. CEO Jason Cohen emphasizes that the firm relies on human tasters and their data as the foundation for its machine-learning models rather than replacing humans with machines. The startup recently closed a $4 million Series A to scale its predictive analytics offerings.

Participated · Series B · Dec 2022

Quadric develops the Chimera GPNPU, a fully programmable general-purpose AI inference processor architecture optimized for on-device AI/ML inference and classic DSP and control algorithms. The Chimera processors scale from 1 to over 3,200 TOPS in multi-chiplet configurations and support both convolutional and transformer-based models, including on-device LLM inference and emerging VLA world models. Quadric's software toolchain converts AI models into C++ and enables SoC teams to program in Python or C++, allowing models to be updated on shipped silicon. The company offers automotive-grade safety-enhanced versions of its architecture and emphasizes a software-updatable approach so the same silicon can run models published after the chip was designed. Quadric reported that product revenues more than tripled in the prior year and that it reached profitability. The company is headquartered in Burlingame, California.

Participated · Series A · Aug 2022

Biotia is a New York, NY health tech company that leverages sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Launched from the Jacobs Technion-Cornell Institute at Cornell Tech, Biotia operates a SUNY Downstate-affiliated CLIA lab at BioBAT in New York City. Its products include a curated genomics reference library for pathogens, clinical-grade metagenomics assays, and a sequencing-based assay to detect SARS-CoV-2 variants that recently received expanded FDA EUA. The company provides software, data, and lab assays to clinicians, laboratories, and public-health organizations for pathogen detection, characterization, research, and surveillance. Biotia plans to grow its diagnostic offerings and expand capacity for global pathogen research and surveillance while rolling out new algorithms and tools for physicians, researchers, and health systems. Financially, Biotia has raised an oversubscribed $8 million Series A and will use the investment to expand technical capabilities, compliance, and marketing reach. Biotia leverages next-generation DNA sequencing (NGS) and proprietary AI software Chelsea™ to rapidly and accurately identify microorganisms and antimicrobial resistance from clinical and environmental samples. Chelsea can detect known and emerging bacteria, fungi, parasites and viruses from a clinically‑curated and annotated database of over 16,000 microbial species and reports predicted drug resistance and virulence markers. The company has built one of the world’s largest precision metagenomics clinical databases by working with hospitals internationally across sample types including urine, stool, blood, sputum and soft tissue. Biotia plans to launch new CAP/CLIA clinical diagnostic tests in early 2020 and is expanding its offerings from environmental testing and research‑use patient tests to patient diagnostics. The company announced an oversubscribed $2.4M seed raise to further develop and implement its diagnostic testing methods and AI software. The executive team includes Co‑Founder and CEO Dr. Niamh B. O’Hara, Co‑Founder Dr. Christopher E. Mason (Global Director), Co‑Founder and CTO Dr. Rachid Ounit, and Chief Medical Officer Dr. Dorottya Nagy‑Szakal.

Participated · Series B · Dec 2021

Adlumin offers a patented, cloud-based security operations platform and managed detection and response services tailored to mid-market organizations. Its single-license platform includes SIEM, vulnerability scanning, threat intelligence, UEBA threat hunting, honeypots, automated incident response and forensics, darknet exposure monitoring, and compliance reporting. The platform is built to be a command center for security operations, pre-integrated with other solutions and designed to enable channel partners, MSPs and MSSPs to deliver expert support. Adlumin emphasizes real-time visibility and collaboration, giving customers and service providers access to alerts, investigation data, reporting and on-demand compliance reports. The company recently introduced a subscription-based incident response service and financial protections including a no-cost warranty and discounted cyber insurance. Adlumin plans to use new funding to accelerate growth, expand and strengthen channel partnerships, and continue innovating to address mid-market needs. The company ranks among the top 10% of America’s fastest-growing private companies and was named to The Information’s 50 Most Promising Startups list for 2023. Adlumin offers a patented managed security services automation platform designed for channel delivery, unifying data streams on-premises and in the cloud to enhance customers’ existing security stacks. The platform advertises a 90-minute installation time, immediate time to value, and serverless scalability. Adlumin emphasizes real-time threat detection, analysis, response, and comprehensive reporting for security operations and compliance. The company is developing additional integrations and value propositions and plans to expand its product vision toward a command center for security operations. Leadership says new capital will support significant investments in product development and a channel program to enable partners to deliver its security analytics more broadly. The company recently added hundreds of customers, received two patents for its serverless data analytics architecture, and earned recognition on the 2021 Inc. 5000 list and CRN’s Emerging Vendors list. Adlumin serves financial institutions, targeting organizations with $100 million to $25 billion in assets. Its core product set includes the Abakis platform, a 24/7 SOC service, the Adlumin Threat Intelligence Portal (ATIP), enriched compliance reporting (FFIEC CAT and NCUA ACET), and patented software to protect core banking systems. The company emphasizes unlimited data scalability via a cloud application and real-time threat detection, analysis, and response. Adlumin participated in the ICBA ThinkTECH Accelerator and was selected as an ICBA Preferred Service Provider, boosting its visibility in the community banking market. As evidence of growth, the company secured a multimillion-dollar F-35 contract with the U.S. Air Force. Adlumin plans to use the new capital to accelerate expansion of the Abakis platform, advance its patented core-banking security technology, and build its brand and product offerings.